OBSV Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (22 kov. 2023 @ 22:00):

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy...

Stats
Dzisiejszy wolumen	8.23M
Średni wolumen	7.95M
Kapitalizacja rynkowa	11.00M
EPS	$0 ( 2024-03-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.138
ATR14	$0.0240 (28.57%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-06	Loumaye Ernest	Buy	4 000 000	Common Shares
2023-02-28	Loumaye Ernest	Buy	4 000 000	Common Shares
2023-02-23	Brown William Michael	Buy	250 000	Employee Stock Option (right to buy)
2023-01-01	Loumaye Ernest	Sell	0	Common Stock
2023-01-01	Mathers Edward T	Sell	32 000	Stock Option (right to buy)

INSIDER POWER
77.21
Last 14 transactions
Buy: 8 250 000 \| Sell: 1 374 140

Wolumen Korelacja

Długi: 0.13 (neutral)

Krótki: 0.22 (neutral)

Signal:(39.484) Neutral

Obseva SA Korelacja

10 Najbardziej pozytywne korelacje
TACT	0.875
EWCZ	0.865
LUNA	0.847
GETVV	0.847
HURN	0.841
SBNYP	0.839
PRFT	0.837
NERV	0.835
INTA	0.831
FRHC	0.83

10 Najbardziej negatywne korelacje
GTLS	-0.877
TNDM	-0.861
TYHT	-0.858
BRY	-0.853
LAUR	-0.849
KALU	-0.848
IIIV	-0.845
TWLVU	-0.845
BZFD	-0.839
HWKN	-0.838

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Obseva SA Korelacja - Waluta/Towar

-0.60
( weak negative )

-0.20
( neutral )

0.00
( neutral )

-0.36
( neutral )

0.60
( weak )

-0.53
( weak negative )

Obseva SA Finanse

Annual	2022
Przychody:	$19.64M
Zysk brutto:	$19.64M (100.00 %)
EPS:	$-0.320

FY	2022
Przychody:	$19.64M
Zysk brutto:	$19.64M (100.00 %)
EPS:	$-0.320

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.337

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.670

Financial Reports:

No articles found.

Obseva SA

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.